Bernstein keeps EUR 44.65 target for Fresenius Medical Care stock

Published on 10/13/2026 at 14:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results arrive on November 3, 2026. Fresenius Medical Care stock costs EUR 38.19 on October 13, 2026, plus 0.66 percent versus October 12, 2026 Xetra close.

Bernstein maintained a Hold rating and set a EUR 44.65 target on October 8, 2026.
Second-quarter revenue reached EUR 4.86 billion, up 1.00 percent year over year.
Fresenius Medical Care stock costs EUR 38.19 at Lang & Schwarz on October 13, 2026 at 2:01 p.m. CEST, plus 0.66 percent versus the Xetra close of October 12, 2026 at EUR 37.94.
Fresenius Medical Care will report third-quarter 2026 results on November 3, 2026.

Modernes Dialysezentrum mit hellblauen Behandlungsstühlen und medizinischen Geräten in klinischer Umgebung — Fotorealistisches Dialysezentrum symbolisiert Fresenius Medical Care AG DE0005785802 mit modernen Behandlungsstühlen in ruhiger klinischer Atmosphäre, Illustration mit AI erstellt.

Bernstein maintained a Hold rating on Fresenius Medical Care and set a EUR 44.65 price target on October 8, 2026, according to Markets Insider. The target lies 16.92 percent above the EUR 38.19 price. Fresenius Medical Care was trading at EUR 38.19 at Lang & Schwarz on October 13, 2026 at 2:01 p.m. CEST, plus 0.66 percent versus the Xetra close of October 12, 2026 at EUR 37.94.

Second-quarter revenue reached EUR 4.86 billion

Fresenius Medical Care reported revenue of EUR 4.86 billion for the second quarter of 2026, up 1.00 percent from EUR 4.79 billion in the second quarter of 2025. The figure came alongside operating income of EUR 466.00 million, up 10.00 percent year over year, according to Europe Says.

Operating income excluding special items increased 20.00 percent to EUR 569.00 million in the same quarter, while the corresponding margin reached 11.70 percent versus 9.90 percent a year earlier. That comparison puts operating improvement ahead of the group revenue trend and gives the upcoming report a clear profitability test.

Stock remains below its yearly high

The latest Lang & Schwarz price is EUR 38.19, while a dated market quote placed the 52-week high at EUR 47.39 on October 12, 2026. The current price is 19.41 percent below that high, calculated from the two euro values. The stock therefore remains closer to its recent trading range than to the analyst target cited by Bernstein.

November 3 is the next reporting date

Fresenius Medical Care's investor-relations calendar lists November 3, 2026 for the third-quarter 2026 earnings release and conference call, followed by the quarterly financial report on November 6, 2026, according to the company's investor-relations calendar. The date gives investors a defined checkpoint for treatment volumes, revenue development and operating profitability.

Price and investor perspective

For investors, the key contrast is between the EUR 44.65 Bernstein target and the EUR 38.19 market price. The 16.92 percent target premium is larger than the 0.66 percent one-day increase against the Xetra close, so the November report will determine whether the operational improvement in the second quarter carried into the next period.

Fresenius Medical Care was trading at EUR 38.19 at Lang & Schwarz on October 13, 2026 at 2:01 p.m. CEST, plus 0.66 percent versus the Xetra close of October 12, 2026 at EUR 37.94. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.